113 related articles for article (PubMed ID: 2592819)
81. Safety of oral hydration after cisplatin infusion in an outpatient lung cancer unit.
Puisset F; Bigay-Game L; Paludetto MN; Martel A; Perriat S; Rabeau A; Canonge JM; Mazieres J
Support Care Cancer; 2019 May; 27(5):1679-1686. PubMed ID: 30120556
[TBL] [Abstract][Full Text] [Related]
82. Supplemental fosfomycin and/or steroids that reduce cisplatin-induced nephrotoxicity.
Umeki S; Watanabe M; Yagi S; Soejima R
Am J Med Sci; 1988 Jan; 295(1):6-10. PubMed ID: 2827472
[TBL] [Abstract][Full Text] [Related]
83. Hypomagnesemia following high-dose intracavitary cisplatin with systemically administered sodium thiosulfate.
Markman M; Cleary S; Howell SB
Am J Clin Oncol; 1986 Oct; 9(5):440-3. PubMed ID: 3776908
[TBL] [Abstract][Full Text] [Related]
84. Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer.
Reece PA; Stafford I; Davy M; Morris R; Freeman S
Cancer Chemother Pharmacol; 1989; 24(4):256-60. PubMed ID: 2752507
[TBL] [Abstract][Full Text] [Related]
85. Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia. Results of a controlled trial.
Martin M; Diaz-Rubio E; Casado A; López Vega JM; Sastre J; Almenarez J
Am J Clin Oncol; 1992 Aug; 15(4):348-51. PubMed ID: 1514533
[TBL] [Abstract][Full Text] [Related]
86. Lack of age-dependent cisplatin nephrotoxicity.
Hrushesky WJ; Shimp W; Kennedy BJ
Am J Med; 1984 Apr; 76(4):579-84. PubMed ID: 6538750
[TBL] [Abstract][Full Text] [Related]
87. [Anticancer chemotherapy containing cisplatin in patients with lung cancer and kidney function].
Wiela-Hojeńska A; Passowicz-Muszyńska E; Orzechowska-Juzwenko K; Jankowska R; Hurkacz M; Unolt J; Weryńska B; Gołecki M; Dyła T
Pol Arch Med Wewn; 2002 Feb; 107(2):135-40. PubMed ID: 12107968
[TBL] [Abstract][Full Text] [Related]
88. Role of epigenetic mechanisms in cisplatin-induced toxicity.
Quintanilha JCF; Saavedra KF; Visacri MB; Moriel P; Salazar LA
Crit Rev Oncol Hematol; 2019 May; 137():131-142. PubMed ID: 31014509
[TBL] [Abstract][Full Text] [Related]
89. Diuretic response to cyclophosphamide in rats bearing a matrix metalloproteinase-9-producing tumour.
Mizushima Y; Sassa K; Hamazaki T; Fujishita T; Oosaki R; Kobayashi M
Br J Cancer; 1998 Oct; 78(8):1030-4. PubMed ID: 9792146
[TBL] [Abstract][Full Text] [Related]
90. Glutathione and detoxification.
Tedeschi M; Bohm S; Di Re F; Oriana S; Spatti GB; Tognella S; Zunino F
Cancer Treat Rev; 1990 Sep; 17(2-3):203-8. PubMed ID: 2272034
[No Abstract] [Full Text] [Related]
91. Multivariate analysis of risk factors for cisplatin-induced nephrotoxicity in gynecological cancer.
Yamamoto Y; Watanabe K; Matsushita H; Tsukiyama I; Matsuura K; Wakatsuki A
J Obstet Gynaecol Res; 2017 Dec; 43(12):1880-1886. PubMed ID: 28984058
[TBL] [Abstract][Full Text] [Related]
92. Evaluation of the Protective Effect of Cystone Against Cisplatin-induced Nephrotoxicity in Patients with Cancer: A Pilot Study.
Tamadon MR; Tirom S; Ghahremanfard F; Baradaran A; Ghorbani R
Int J Prev Med; 2019; 10():180. PubMed ID: 32133098
[TBL] [Abstract][Full Text] [Related]
93. [Preventive effect of urinastatin on cisplatin induced nephrotoxicity in rabbits].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Mar; 41(3):328-32. PubMed ID: 2567322
[TBL] [Abstract][Full Text] [Related]
94. [Cisplatin and ovarian carcinoma--early detection of cisplatin-induced nephrotoxicity].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Jun; 37(6):888-96. PubMed ID: 4040542
[TBL] [Abstract][Full Text] [Related]
95. [New treatments for urogenital toxicity of anti-neoplastic chemotherapy].
Shibuya M; Hirosawa A; Niitani H
Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 2):950-6. PubMed ID: 2111664
[TBL] [Abstract][Full Text] [Related]
96. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
97. [Preventive effect of urinastatin on cisplatin-induced nephrotoxicity].
Kobayashi H; Ishizuka H; Hirashima Y; Ohi H; Demukai H; Moniwa M; Maeda M; Kobayashi T; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1959-64. PubMed ID: 2592819
[TBL] [Abstract][Full Text] [Related]
98. [Effects of urinastatin against nephrotoxicity of cisplatinum].
Arakawa A; Kato N; Asai H; Yasui Y; Suzumori K; Suzumori K; Yagami Y
Gan To Kagaku Ryoho; 1990 Nov; 17(11):2229-34. PubMed ID: 2241187
[TBL] [Abstract][Full Text] [Related]
99.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
100.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
